Evidence map›Paper›PMID 40047406›Full record

ArticleeLife2025

Regulation of lung cancer initiation and progression by the stem cell determinant Musashi.

Alison G Barber, Cynthia M Quintero, Michael Hamilton, Nirakar Rajbhandari, Roman Sasik, Yan Zhang, Carla Kim, Hatim Husain, Xin Sun, Tannishtha Reya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alison G BarberDepartment of Pharmacology and Medicine, University of California San Diego School of Medicine, La Jolla, United States.
Cynthia M QuinteroDepartment of Pharmacology and Medicine, University of California San Diego School of Medicine, La Jolla, United States.
Michael HamiltonDepartment of Pharmacology and Medicine, University of California San Diego School of Medicine, La Jolla, United States.
Nirakar RajbhandariDepartment of Pharmacology and Medicine, University of California San Diego School of Medicine, La Jolla, United States.
Roman SasikCenter for Computational Biology and Bioinformatics, University of California San Diego School of Medicine, La Jolla, United States.
Yan ZhangDepartment of Pediatrics, University of California, San Diego, La Jolla, United States.
Carla KimStem Cell Program, Division of Hematology/Oncology and Division of Respiratory Disease, Boston Children's Hospital, Boston, United States.
Hatim HusainMoores Cancer Center, University of California San Diego School of Medicine, La Jolla, United States.
Xin SunDepartment of Pediatrics, University of California, San Diego, La Jolla, United States.
Tannishtha ReyaDepartment of Pharmacology and Medicine, University of California San Diego School of Medicine, La Jolla, United States.ORCID https://orcid.org/0000-0002-5956-8536

Funding

Molecular strategies for early detection and targeting of cancerR35CA197699 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tannishtha Reya · 2015 to 2026
$11.2M
Blood Cells in Hemostasis and ThrombosisT32HL086344 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2008 to 2023
$4.4M
NCI NIH HHS R35 CA197699NHLBI NIH HHS T32 HL086344NIH HHS R35 CA197699NIH HHS T32 HL086344
6 · The paper itself

Abstract

Despite advances in therapeutic approaches, lung cancer remains the leading cause of cancer-related deaths. To understand the molecular programs underlying lung cancer initiation and maintenance, we focused on stem cell programs that are normally extinguished with differentiation but can be reactivated during oncogenesis. Here, we have used extensive genetic modeling and patient-derived xenografts (PDXs) to identify a dual role for Msi2: as a signal that acts initially to sensitize cells to transformation, and subsequently to drive tumor propagation. Using Msi reporter mice, we found that Msi2-expressing cells were marked by a pro-oncogenic landscape and a preferential ability to respond to Ras and p53 mutations. Consistent with this, genetic deletion of

Indexed as

CarcinogenesisLung NeoplasmsNeoplastic Stem CellsNerve Tissue ProteinsRNA-Binding ProteinsAnimalsDisease Models, AnimalDisease ProgressionHumansMiceTumor Suppressor Protein p53Msi2h protein, mouseMSI2 protein, humanNerve Tissue ProteinsRNA-Binding ProteinsTumor Suppressor Protein p53cancer biologycancer stem cellscell of originhumanlung cancermouseMusashi-2NSCLCregenerative medicinestem cells

Identifiers

PMID40047406
PMCPMC11884785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.